hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 19:59:24 - browse：2

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FDA scientists endorse Pfizer/BioNTech Covid

knowledge

WSS

How I helped Pfizer think through the ethics of Viagra

Pushing for an NIH office for post

How many hemophilia patients actually want gene therapy?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How I helped Pfizer think through the ethics of Viagra

Biotech startup Celsius cuts 75% of staff ahead of first trial start

hotspot

hotspot

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

H.R. 3 is the wrong path to lower drug costs

Bright Health sells Medicare Advantage business to Molina

RaDonda Vaught links Vanderbilt hospital issues to patient death

BioMarin wins approval for gene therapy to treat hemophilia A

Personalized medicine goes far beyond genetics

Bright Health sells Medicare Advantage business to Molina

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Continuity nursing helped my family in our darkest PICU moments

How many hemophilia patients actually want gene therapy?

focus

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Alnylam reports growth in sales of rare disease treatments

John Green on his newest strategy for fighting tuberculosis

2 officers injured in shooting in Orlando, police say

Study links childhood stress with decline in older age

Readout Newsletter: CAR

knowledge

explore

knowledge

entertainment